Shire May Split Up – But Punting On Bigger Decisions For Now

The specialty pharma is dividing its operations into rare disease and neuroscience units, but whether that will mean a spinout for the latter won't be revealed for months.

Headed for danger business concept as a man walking on a straight road towards a group of dangerous sharks as a metaphor and symbol of risk and courage from a person on a career path or life journey.

Following through on a strategy it first began talking about last August, Shire PLC announced Jan. 8 that it is creating "two distinct divisions" within the company – one focused on rare diseases, the other on neuroscience – and will begin reporting the operational metrics of each unit starting with its first quarter earnings report.

Intentionally left up in the air is whether Shire is thinking about a spinout or an initial public offering for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Otsuka’s IgAN Data Top Some Vera Results, But To What End?

 
• By 

Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By 

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Europe’s Drugmakers Lament EU Pharma Package

 
• By 

EFPIA says reforms make the continent less attractive for innovative firms.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By 

US green light will further expand sales of the prostate cancer blockbuster.

More from Business

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

 

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.

Europe’s Drugmakers Lament EU Pharma Package

 
• By 

EFPIA says reforms make the continent less attractive for innovative firms.

Deal Watch: Lilly Licenses Camurus’s Delivery Technology For Long-Acting Incretins

 
• By 

Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.